SeekingAlpha · Mar 26, 2026
Bayer: Turnaround Is Underway - Don't Miss It
Bayer stays a Buy as litigation overhang eases. See intrinsic value at â¬70.81, free cash flow upside post-2026, and growth outlookâread more.

OTC · BAYRY
Healthcare · Drug Manufacturers - General
$14.02
Down-$0.04 (-0.28%)
Updated Aug 24, 2026, 2:00 PM
SID Score
6.0/10
Composite research score
Smart Money
43/100
Neutral
Price performance
1M range · 0 trading sessions · Daily adjusted prices
BAYRY does not have enough price history for the selected period.
Data unavailable
The requested market data was not found.
The latest Smart Investors Daily articles mentioning BAYRY.
BAYRY research
Company profile and research snapshot.
BAYER AG S/ADR
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jul 13, 2026 | BERENBERG | Hold | — |
| Jul 13, 2026 | JEFFERIES | Hold | — |
| Jul 12, 2026 | LANDESBANK BADEN-WUERTTEMBERG | Buy | — |
| Jul 12, 2026 | DAY BY DAY | Buy | — |
| Jul 8, 2026 | ROTHSCHILD & CO REDBURN | Buy | — |
No generated briefing is available yet.
SeekingAlpha · Mar 26, 2026
Bayer stays a Buy as litigation overhang eases. See intrinsic value at â¬70.81, free cash flow upside post-2026, and growth outlookâread more.
Benzinga · Feb 18, 2026
Bayer AG (OTC: BAYRY) on Tuesday proposed a $7.25 billion settlement to resolve thousands of U.S. lawsuits claiming that its weedkiller Roundup causes cancer. The product was originally made by Monsanto, which Bayer acquired in 2018 for more than $60 billion.
SeekingAlpha · Feb 17, 2026
Benzinga · Feb 17, 2026
https://www.bloomberg.com/news/articles/2026-02-17/bayer-to-make-10-5-billion-push-to-settle-roundup-cases
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.


The latest Smart Investors Daily articles mentioning BAYRY.